Dr.

Lal PathLabs Limited (DLPL)

Corporate
Presentation
November 2020
Disclaimer
By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations:

The information in this presentation has been prepared by Dr. Lal PathLabs Limited (the “Company”) for use in presentations by the Company at analyst and investor meetings and does not
constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness,
accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability
whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The
information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its
advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements
that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements
involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain
risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of
these uncertainties, readers should not unduly rely on these forward looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking
statements or to adapt them to future events or developments.

This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with
any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and
the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the
Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not
be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from
registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished
to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation nor
any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in
compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or
other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted.

By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of
Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or
benefit of a U.S. person.

2
 Table of Contents

Company overview 4

Investment highlights 9

Q2 FY21 highlights & financial performance 21

DLPL strategy for future growth 34

DISCLAIMER: This presentation may contain ‘forward-looking’ statements at places. The Company’s business operations remain subject to undetermined contingencies and risks. Dr. Lal PathLabs
Limited would not be liable for any action undertaken based on such ‘forward-looking’ statements and does not commit to revising/updating them publicly.

3
Company Overview
Dr. Lal PathLabs at a glance
Our Evolution
Dr. Lal PathLabs overview
Experienced Management team

4
 Dr. Lal PathLabs – At a Glance

India’s Leading & Trusted 12% 15% 120%

Diagnostics Company Largest* 3 Year Revenue 3-Year PAT Equity Dividend
CAGR CAGR for FY 19-20
diagnostics
70+ years of experience chain in the
in the field of diagnostics country with ~67% Rs 894.1 Cr.
PAN India ROCE Cash & Investments as on
presence and Excl. Cash & 30th Sep 20
77.5 Mn patients Investments
serviced in last 5 years
consistent track
record of
quality and 216 4,953 CRISIL AA-
33 NABL accredited Labs;
growth Labs; Pathology & /Stable
National Reference Lab Geographically Radiology tests;
Comprehensive Long Term Rating;
accredited by CAP spread out
network Test menu Strength of Balance
Sheet
As on March 31, 2020
*Largest on the basis of Revenue and presence 5
 Our Evolution

1949 – 2005 2010 – 2015

Strong position in
North India,
Foundation
2005 – 2010 building network 2015 onwards
in other
Higher contribution
Building geographies
from Rest of India,
capabilities for Commissioned state
scale up  Investment by TA Associates
 1949: Founded by Dr. Major S. K. of the art Kolkata
 Clinical laboratories expansion in Reference Lab
Lal
North region
 1995: Company incorporated as  Higher contribution from Rest of
 Growing the business in
Dr. Lal PathLabs Private Ltd.  2005: onwards: Investment by India business & focus on bundled
East region
test program “Swasthfit”
 2000: Three clinical labs receive WestBridge Capital
 Entry into the South and West
NABL1 accreditation  2008: Acquisition of Paliwal  Successful commissioning of
regions
Regional Reference Lab at Kolkata in
 2001: Received ISO 9001:2008 Medicare Private Limited and
 Multiple acquisitions to 2018
certification Paliwal Diagnostics Private Limited
scale network
 2010: National Reference Lab set  Inorganic growth through acquisition
 2002: Received ’International
 Successful IPO listing in Dec 2015 of laboratories in Western &
Accreditation’ from CAP2 up in Delhi
Southern India

1. NABL: National Accreditation Board for Calibration and Testing Laboratories.

2. CAP: College of American Pathologists. 6
 Dr. Lal PathLabs overview
Established consumer healthcare brand in diagnostic services Routine testing Specialized testing

Bio- Molecular
Pan-India integrated coverage with 216 clinical labs
chemistry diagnostics
(including National Reference Lab1 at Delhi and Regional Ref Lab at

Test Menu
Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up
Points (PUPs)2 Hematology
Flowcytometry
Clinical pathology
Catalogue of 455 test panels, 2,537 pathology tests
and 1,961 radiology and cardiology tests2 Genetics / Cytogenetics
Microbiology
Collected and processed ~13.2 mn samples from ~5.4 mn patients
in Q2 FY21; ~47.7 mn samples from ~19.4 mn patients in FY20; Basic radiology Histopathology
~41.8 mn samples from ~17.6 mn patients in FY19

Accreditations
Customers include individual patients, corporates and institutions,
healthcare providers as well as hospital and clinical labs (lab
management)

FY20: Revenue: INR 1,330.4 Cr.; EBITDA: INR 331.1 Cr3 ISO15189:2007
(Margin: 24.9%); PAT: INR 227.6 Cr (Margin: 17.1%); 33 Labs IS9001:2008
FY19: Revenue: INR 1,203.4 Cr; EBITDA : INR 313.2 Cr ISO27001:2013
(Margin: 26%); PAT: INR 200.5 Cr (Margin: 16.7%)
1. Total area of 7,253 square meters
2. As on March 31, 2020.
3. Normalised EBITDA excl ESOP, CSR Cost & impact of Ind AS 116 7
 Experienced Management team

(Hony.) Brig. Dr. Arvind Lal Dr. Om Manchanda Dr. Vandana Lal Bharath Uppiliappan Ved Prakash Goel
Executive Chairman Managing Director Whole-time Director Chief Executive Officer Chief Financial Officer

Shankha Banerjee Munender Soperna Rajat Kalra Manoj Garg

Company Secretary and Compliance
Chief Operating Officer Chief Information Officer Chief Human Resources Officer
Officer

8
Investment Highlights

9
Investment Highlights

Well-positioned in one of the

Established consumer healthcare
fastest-growing segments of the
brand in diagnostic services
Indian healthcare industry

Attractive operating metrics and Scalable model integrated through

multiple levers in place to drive next centralized IT platform allows for
phase of growth network expansion

Robust financial
performance and return on
invested capital

10
 Indian Healthcare Services is a large growth opportunity

India’s expected India’s Public healthcare Private expenditure on

India GDP in FY201
population in 2022 expenditure in FY 20 healthcare in 2015

India, highly
Total Healthcare Expenditure as % of GDP (2015) underpenetrated
17.1%
market

11.2%
8.9% 8.2%
5.6% 5.3% 4.3% 3.9% 3.3%

US Germany Brazil South Africa Russian Federation China Singapore India Indonesia

Source: CRISIL Report titled “Assessment of Diagnostics Industry in India”.

1. Financial Year ending March 31st.
2. Source: Report of the Insurance Regulatory and Development Authority (“IRDA”) 11
3. Source: World Health Organization Global Health Expenditure database, October 2017, 4. IMF
INR 596 Bn Diagnostic Services industry expected to grow
to INR 924 Bn in 2022
Diagnostic Services Industry Size Growth Drivers
INR 924 Bn

INR 596.1 Bn
Increase in
Demand evidence-based
for lifestyle treatments
diseases-related
services
to grow
2017-18E 2021-22P

Focus on
Screening, early detection, preventive
diseases and
and monitoring reduce wellness
downstream costs

Source: Industry Reports, I-Sec Research

12
 Diagnostic Services industry remains highly fragmented

Highly Fragmented Industry

Large
Standalone Pan-India
Centres, 48% Chains 35-40%
Diagnostic
Chain, 15% Regional
Chains
60-65%
Hospital
Based, 37%

Largely fragmented and unorganized

Source: CRISIL Report titled “Assessment of Diagnostics Industry in India”.
13
 Established consumer healthcare brand in Diagnostic Services
Pillar of a
Strong Brand
Medico Marketing
Doctor
Online
 Accreditations from Call
Centre
Query Handling Registration
CAP, NABL and ISO Offline
Accreditations
 Centrally administered
surveillance programs
Online Customer Lab
 Coverage in metros, Report Delivery Sample Collection
Tier 1 and Tier 2 cities Nationwide Offline Home
 Wide reach through Network
PSCs and PUPs
Retail Marketing Digital Marketing

 24x7 access including

online access and Fast Walk-in customers
Single brand pulls Diverse and large
account for highest
home collection Turnaround patients
share of revenues
customer pool
 Dedicated logistics Time
team

14
 Scalable Model integrated through centralized IT platform allows
for network expansion
Hub and Spoke Model Network Expansion
PSC PSC
No. of
Reference Clinical No. of PSCs No. of PUPs
Lab Laboratories
6,995
216 6,426
3,095
Clinical Clinical 5,624
Lab Lab 2,569
2,153
200
PSC PSC
PSC PSC
193

• Centralized diagnostic testing provides

greater economies of scale
• PSCs and PUPs facilitate penetration FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20
within region and expand reach

1. Includes National Reference Laboratory and Regional Reference Lab in Kolkata

15
Scalable Model integrated through centralized IT platform allows
for network expansion
Integrated National Network… …backed by Centralized IT platform
which fully integrated network

Enterprise Resource Planning (ERP) System

 Payables, receivables, inventory, ledgers etc.

 Scalability and connectivity – web-based

Laboratory Information Management System

 Bi-directional interface; tracks specimen

collection, shipping and testing in real time
 Assigns unique ID / barcode for each sample

Data Collection and Analytics

National Reference Laboratory
Regional Reference Laboratory  Improve diagnostic services via data analyses
Clinical Laboratories  Demand for tests are analyzed using past data
Patient Service Centers

16
 Collection network

LPL’s scalable business model provides strategic advantage for expansion and consolidation

National Reference Lab & Regional

Ref. Lab

Single brand pulls patients

Clinical Labs
(Testing/Collection)

Walk-in customers account for

Patient Service Centers Pickup Points highest share of revenues

Home
Walk-ins
Collection Hospitals Doctors Labs Diverse, large customer pool
Walk-ins offers monetization
opportunities

17
 Attractive operating metrics
No. of patients No. of samples Total Revenue
(Mn) (Mn) (INR Cr.)

CAGR: 13.0% CAGR: 17.2% CAGR: 12.2%

1,330.4
19.4 47.7 1,203.4
17.6 41.8 1,056.9
15.2 34.7

FY18 FY19 FY20 FY18 FY19 FY20 FY18 FY19 FY20

 FY20 Revenues increased on

account of :
 Consumer brand and network  Increase in samples with patient  Marked gains in patient volumes
expansion driving patient volumes volumes growth at 10.3%
 Increase in tests per patient at
2.5 vs 2.4

18
Robust financial performance
Total Revenue South Others
3%
EBITDA*,PAT and Return on Net Worth
(INR Cr.)
India (INR Cr./%)
West 6%
CAGR: 12.2% India
8% 313.2 331.1
1,330.4
1,203.4 278.3
1,056.9 East 227.6
200.5
India Revenue by 171.8
14% Geography
(FY20)
Delhi &
NCR FY18 FY19 FY20
Rest of 40%
EBITDA before ESOP Expense ,CSR & PAT
North India Ind AS 116 impact*
FY18 FY19 FY20 29%
EBITDA Margin
Before ESOP,
CSR & Ind As 116
26.3% 26.0% 24.9%
impact

• Growth driven primarily by increasing patient volumes and samples PAT Margin 16.3% 16.7% 17.1%
RONW 24.7% 23.0% 22.7%
• Increase in operating margin due to economies of scale

19
 Robust financial performance (Cont’d)

Fixed Asset Turnover1 Cash and Cash Equivalents

Times (INR Cr.)

 Self funded growth on

account of strong cash flow
8.5x
generation
7.5x 580.0
6.6x 522.9  Attractive fixed asset
405.8
turnover ratio given asset-
light model
 Current net cash position
184.8
144.8 164.3 and internal accruals
expected to fund next phase
of growth
FY18 FY19 FY20 FY18 FY19 FY20

Cash and Bank Balance Current Investments

1. Fixed Asset Turnover = Total Revenue / Net PP&E as per Ind AS

20
Q2 FY21 Highlights &
Financial Performance

21
Q2 FY21 Snapshot

18.2% 18.7% *7.5%

INR 431.9 Cr INR 134.7 Cr INR 87.1 Cr

Revenues Normalised EBITDA* PAT

1.1% 1.1%

~ 5.4 mn ~ 13.2 mn
Patients Samples

* PAT in Q2 last year has high base due to Income tax rates reduction benefit pertaining to Q1 as well 22
Overview of Dr. Lal PathLabs

Established brand Pan-India integrated Varied Offerings Unique and successful

coverage operating model

216 clinical labs (including

National Reference Lab at Catalogue of 455 test panels, Scalable model integrated
Established consumer
Delhi and Regional Reference 2,537 pathology tests and through centralised IT
healthcare brand in diagnostic
lab at Kolkata), 3,095 Patient 1,961 radiology and platform allows for network
services
Service Centers (PSCs) and cardiology tests* expansion
6,995 Pick-up Points (PUPs)*

Well-positioned in one of the fastest-growing segments of the Indian healthcare industry

As on March 31, 2020

23
COVID & Non-COVID Revenue

568 • Non-COVID business back to 98% of last

year levels in Q2 FY21
• Contribution from COVID business in Q2
358 FY21 is ~17%.

210 • 3.08 lac COVID RTPCR tests conducted in

130
Q2 FY21 and 5.05 lac in FH FY21
56 74
• RT-PCR test being conducted in 9 labs.
• Commenced on-demand testing for
Q1 FY21 Q2 FY21 FH FY21 COVID as per Govt norms
Non COVID COVID*

*COVID includes RTPCR and Antibody Tests only

24
 Key Performance Highlights
During Q2 FY21:

• Revenues increased by 18.2% Y-o-Y at Rs. 431.9 crore

• Normalised EBITDA (after eliminating the impact of stock based compensation & CSR) at Rs. 134.7 crore
• Profit After Tax at Rs. 87.1 crore, representing a growth of 7.5% over the corresponding quarter of last year
• Interim dividend of Rs. 6 per equity share of Rs. 10 each has been approved by the Board

Cash, FDs and Mutual Funds at Rs. 894.1 crore as on September 30, 2020, an increase of Rs. 150 crores in FH
FY21

Business momentum achieved in the month of Jun’20 accelerates in Q2 FY21

• Non-COVID business almost back to normal level in Q2 FY21 at Rs. 358 crores
• Patient volumes grew by 1.1% Y-o-Y at 5.4 million
• Binding term sheets signed to acquire 100% stake in Bindish Diagnostic Laboratory, Jamnagar and 70% stake in
Chanre Diagnostics Laboratory; having revenue of Rs 3.2 crores & Rs 11.5 crores respectively for FY 20

25
 Financials

Particulars (Rs. Cr.) Q2 FY21 Q2 FY20 Gr % FH FY21 FH FY20 Gr %

Total Revenue 431.9 365.6 18.2% 697.9 700.8 -0.4%
Total Expenditure 304.7 256.7 522.4 496.8
EBITDA 127.3 108.9 16.9% 175.5 204.0 -14.0%
Adj for Stock based comp. & CSR cost 7.4 4.6 13.0 8.5
Normalised EBITDA 134.7 113.5 18.7% 188.5 212.5 -11.3%
Normalised Margins 31.2% 31.0% 27.0% 30.3%
Other Income 12.9 14.8 24.3 29.2
PBT 116.6 102.3 14.0% 154.7 191.7 -19.3%
Margins 27.0% 28.0% 22.2% 27.4%
PAT 87.1 81.0 7.5% 115.5 140.1 -17.6%
Margins 20.2% 22.2% 16.5% 20.0%
EPS (Basic) 10.34 9.77 5.8% 13.79 16.91 -18.4%
EPS (Diluted) 10.31 9.75 5.7% 13.75 16.86 -18.4%

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be influenced
by certain occurrences in that quarter 26
 Financial Highlights
All figures in Rs. Crore
+18.2%
• Revenue increased in Q2 FY21 by 18.2% to Rs. 431.9
431.9
crore. This is on account of :
– Volumes which increased by 1.1% and
– Revenue from COVID testing
Revenue 365.6
• Realisation per patient in Q2 FY21 at Rs. 803, higher as
compared to Rs. 687 in Q2 FY20

Q2 FY20 Q2 FY21

+18.7%
• Normalised operating EBITDA (after eliminating the
Normalised EBITDA (after 134.7 impact of stock based compensation and CSR costs) at Rs.
eliminating the impact of 134.7 crore in Q2 FY21, higher by 18.7% Y-o-Y
stock based compensation, • Q2 FY21 Normalised EBITDA margin (after eliminating the
113.5
and CSR costs) impact of stock based compensation and CSR costs) came
in at 31.2%
Q2 FY20 Q2 FY21

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be
influenced by certain occurrences in that quarter
27
 Financial Highlights
All figures in Rs. Crore
+14.0%
• PBT for Q2 FY21 at Rs. 116.6 crore vs. Rs. 102.3 crore in
116.6 the corresponding quarter of last year, representing a
growth of 14.0%
PBT • Q2 FY21 PBT margin at 27.0%, as against 28.0% in the
102.3 same period of last year

Q2 FY20 Q2 FY21

+7.5%

87.1 • PAT at Rs. 87.1 crore in Q2 FY21 as compared to Rs. 81.0

crore in Q2 FY20, higher by 7.5%
PAT • Q2 FY21 PAT margin at 20.2% Vs. 22.2% in Q2 FY20
81.0

Q2 FY20 Q2 FY21

Financial results of the Company are best monitored on a year to date basis, as there is a certain level of seasonality in business and specific quarter performance may be
influenced by certain occurrences in that quarter
28
Management Commentary
Commenting on the results announcement, (Hony) Brig. Dr. Arvind Lal, Executive Chairman

“The CoVID-19 pandemic has been fairly prolonged not only affecting the daily lives of people but also impacting the businesses
and economies across the globe. Q2 saw the lockdown being lifted in a phased manner and accordingly we witnessed substantial
recovery where our business growth almost returned back to pre-COVID levels. While patients are still hesitant to access medical
facilities, sales have started recovering as the number of walk-in patients has been increasing gradually”

Commenting on the results announcement, Dr. Om Manchanda, Managing Director

“Healthcare services across the board are normalizing with nearly the entire country having opened up and that will anchor the
pattern in diagnostics in the coming months. Having said that, we feel Covid 19 related testing will continue to contribute a
substantial portion to our revenue for a at least a few more quarters. We are currently doing Covid19 tests at 9 Labs. This is part of
our long-term investment in infrastructure, which later can be used for other specialized testing as the Covid19 testing volume
dries up.”
Commenting on the results announcement, Bharath Uppiliappan, Chief Executive Officer

“While the quarter continued to be challenging from an operations perspective we were able to bring our Non- Covid business to
98% of Q2 FY 20 level. As the country moved to on demand testing for Covid 19 we also had to significantly re-orient our source of
customers from government led to more private and individual led. We also continued to progress well on our key priorities to
drive future growth and capabilities.”

29
Vibrant Outlook
Strongly develop Rest of India geographies, through Regional
Reference Labs and cluster city approach for attractive markets

Target
to grow
Evaluate best fit inorganic Deeper Penetration within the
ahead
opportunities in South & West North, East & Central Indian
of the
markets
industry

Higher contribution from bundling of

tests – ‘Swasthfit’

30
 Leveraging digital to make life easier for patient

Logistics Lab Operations Business

Digital Lab e-Commerce Mobile app
Automation Automation Continuity Plan

• Self Registration • Online test / health • Test booking, view • Field Executive • Totally integrated • ‘Multi Site’ model
Kiosk for patients package booking and download Mobile App for Track with • Quick recovery in
• Integrated payment • Online payment, current and Route Traceability & centralized LIMS for case of disaster
gateway for online order related historical test Field Executive higher Output and • Real time Data
payment notifications at reports Tracking faster processing, Replication
• Self Report printing various touch points • Trend chart along • Real Time visibility built in analytics and between sites
Kiosks for 24 by 7 • Integrated Cross with Cumulative of patient samples Business Intelligence • Centrally
Report printing Channel Reporting capabilities Hosted and
similar to a bank communication with • Find a Lab near you real time
ATM strong automated • Self Monitoring – monitored
backend using cloud, My Wellness
predictive analytics
& AI
• Phlebo Mobile App
for home collection
booking along with
route plan.

31
Shareholding as of 30th September, 2020
22.4%
FIIs

14.1% 55.2%
Others Promoter and
Promoter
Group

8.3%
Mutual Funds*

*Mutual Funds includes Alternate Investment Funds as well

32
 Vision, Mission & Values

VISION

Customer First
Be the most trusted healthcare partner, enabling
healthier lives Ethics & Integrity

VALUES Quality

To be the undisputed market leader by providing

accessible, affordable, timely and quality healthcare, Accountability
diagnostics, applying insights and cutting edge
technology to create value for all stakeholders Empathy & Compassion

MISSION

33
DLPL Strategy for future growth

34
DLPL Strategy for future growth

1 2
Strengthen
Expansion in
Existing
Offering
Operations

Expand

4 3
management of
Geographic
hospital based
expansion
and clinical
laboratories

35
 DLPL Strategy for future growth

Expand management of hospital

Strengthen Existing Operations Expansion in Offering Geographic expansion
based and clinical laboratories

Boosting quality & reliability Improve breadth of

Tap incremental contracts for Focus city & cluster approach
standards diagnostic testing
in sourcing test of hospitals
Improving turnaround times and other clinical laboratories Set up more clinical
Cutting edge technology
for testing laboratories

Preventive healthcare Tap polyclinics Set up Regional Reference

Grow basic radiology practice
screening Laboratories

Online initiatives and data Chronic & Lifestyle disease Consider alliances and
analytics mgmt. services acquisitions

Expand reach in corporate

Investment in branding
segment

36
 Consistent investments in R&D
DSIR recognized In House R&D unit
R&D Collaboration with marquee Successful commercialization of
with an experienced team of
institutions tests
research scientists and doctors

Jawaharlal Nehru University for development of

diagnostics kit for detection of mycobacterium  Spino-Bulbar-Muscular
tuberculosis and mycoabacterial species Atrophy
 Sickle Cell Trio Prenatal
Mutation Detection
 Sanger Sequencing,
Single Variant
 Leigh Syndrome
CSIR-Institute of Genomics and Integrative Mitochondrial
Biology for acquisition of know-how for 27
Mutation Detection
diagnostic assays
 Episodic Ataxia Type 2

37
 Genevolve: The Genomics initiative

GENEVOLVE brings the dawn of a new era of Genomic testing!

Genevolve: Genomics division focuses on Genetic testing

Offers wide range of key tests related to Oncogenomics,

Neurogenomics, Rare disease & Pre-natal/ Post-natal New Tests New Tie-ups ONCOPATH

• Sperm DNA • Caris MI (USA) • Niche

Tests are carried out using cutting edge technologies such as • Caris Tumor Segmentation
• Y Chromosome
Next Generation Sequencing (NGS), MLPA, ddPCR, FISH & Sanger Seek
Sequencing among others

PAN India network of clinical laboratories, collection centers and

pick- up points makes Dr. Lal PathLabs the most reliable genetic
testing service provider in India

38
In-house adoption of Digital Histopathology

 Reporting of Digital Opportunities created by

Breast cancer Panels Digital Histopathology
using AI based
algorithms
 Digital Histopathology • Enhanced access to second
for remote routine opinion, synchronous review
reporting of slides
• Enhanced quality of reporting
• Potential for insourcing
services
More than 30,000 • Leveraging Artificial
slides processed in Q2 Intelligence for Histopathology
FY 21 • Potential for de-centralization
of histopathology reporting

39
Highest Quality Standards in the Industry

100+ Quality Digitally enabled

Real time quality Risk based improvement solutions
control quality assurance meetings on a daily implemented for
monitoring framework basis with the quality audits
network partners and trainings

Best in the Industry CAP Proficiency Testing Score at 98.3% for National Reference Lab

Consistently high EQAS Performance Testing Score at 98.7% for Satellite Labs

NABL Accreditation granted to 7 additional Labs for processing Covid-19 samples

40
Best in class Logistics and Supply Chain management

Real Real time

time service
sample monitoring
tracking Control
tower

Real time
Field Automated
Cash Productivity
Executive
collection and route
tracking
process planning
with clients visibility

24
Enhanced Customer Experience in Home Collection
Auto Routing engine to
dynamically allocate the
booking to nearest available
phlebotomist

Real time slot confirmation Real time phlebo visibility to

to patient the patient

Variable model which grows ECG at home service

with business volume launched in select cities

Automated and scalable

system

25
 Key Awards & Recognition
Dr. Om Manchanda honoured
and awarded as ‘Healthcare
Personality of the Year, 2020’
by FICCI
Computerworld Honors
Laureate Program, 2012
ICICI Lombard & CNBC
TV18 India Risk
Management Awards 2020
– Emerging Corporates
Frost and Sullivan 4th
Annual India Healthcare
Excellence Award,
'Diagnostic Service Provider
Company of the Year 2012'
EY Entrepreneur of The Data Quest Technology VC Circle Healthcare
Year 2019 – Life Award 2015 – Excellence Summit 2013 – Best
Sciences & Healthcare in Implementation of Diagnostic Company
Technology
Franchise India Excellence Franchisor of the Year Padma Shri – (Hony)
Award in Hall of Fame (Healthcare) - Franchise Brig. Dr. Arvind Lal
Category (2011, 2012) Plus Awards 2010 (2009)
43
Contact Us

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services.
It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related
healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other
health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The
catalogue of services includes 455 test panels, 2,537 pathology tests and 1,961 radiology and cardiology tests as on March 31, 2020.
As on March 31, 2020, DLPL’s has 216 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095
Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). In FY19 & FY20, DLPL collected and processed approximately 41.8 million
samples and 47.7 million samples from approximately 17.6 million and 19.4 million patients, respectively.
Additional information on Dr. Lal PathLabs Limited: Corporate Identification No: L74899DL1995PLC065388
Website: https://www.lalpathlabs.com

Ved Goel / Rajat Kalra Siddharth Rangnekar / Nishid Solanki

For further Dr. Lal PathLabs Limited CDR India
information Tel: +91 124 301 6500 Tel: +91 22 66451209 / 1221
please contact: Fax: +91 124 423 4468 Fax: +91 22 66451213
E-mail: ved.goel@lalpathlabs.com/rajat.kalra@lalpathlabs.com Email: siddharth@cdr-india.com / nishid@cdr-india.com

44